Literature DB >> 17008702

Magnetic resonance imaging captures the biology of ductal carcinoma in situ.

Laura J Esserman1, Anjali S Kumar, Alex F Herrera, Jessica Leung, Alfred Au, Yunn-Yi Chen, Dan H Moore, Daniel F Chen, Jennifer Hellawell, Dulcy Wolverton, E Shelley Hwang, Nola M Hylton.   

Abstract

PURPOSE: Magnetic resonance imaging (MRI) is an important tool for characterizing invasive breast cancer but has proven to be more challenging in the setting of ductal carcinoma in situ (DCIS). We investigated whether MRI features of DCIS reflect differences in biology and pathology. PATIENTS AND METHODS: Forty five of 100 patients with biopsy-proven DCIS who underwent MRI and had sufficient tissue to be characterized by pathologic (nuclear grade, presence of comedo necrosis, size, and density of disease) and immunohistochemical (IHC) findings (proliferation, Ki67; angiogenesis, CD34; and inflammation, CD68). Pathology and MRI features (enhancement patterns, distribution, size, and density) were analyzed using pairwise and canonical correlations.
RESULTS: Histopathologic and IHC variables correlated with MRI features (r = 0.73). The correlation was largely due to size, density (by either MRI or pathology), and inflammation (P < .05). Most small focal masses were estrogen receptor-positive. MRI enhancement patterns that were clumped were more likely than heterogeneous patterns to be high-grade lesions. Homogenous lesions were large, high grade, and rich in macrophages. Presence of comedo necrosis and size could be distinguished on MRI (P < .05). MRI was most likely to over-represent the size of less dense, diffuse DCIS lesions.
CONCLUSION: The heterogeneous presentation of DCIS on MRI reflects underlying histopathologic differences.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17008702      PMCID: PMC4087112          DOI: 10.1200/JCO.2005.04.5518

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  28 in total

1.  Prophylactic mastectomy in women with a high risk of breast cancer.

Authors:  V L Ernster
Journal:  N Engl J Med       Date:  1999-06-10       Impact factor: 91.245

2.  [MRI of ductal carcinoma in situ of the breast: patterns of findings and evaluation of disease extent].

Authors:  H Hiramatsu; T Ikeda; M Mukai; S Masamura; K Kikuchi; K Hiramatsu
Journal:  Nihon Igaku Hoshasen Gakkai Zasshi       Date:  2000-03

3.  Biologic significance of false-positive magnetic resonance imaging enhancement in the setting of ductal carcinoma in situ.

Authors:  Anjali S Kumar; Daniel F Chen; Alfred Au; Yunn-Yi Chen; Jessica Leung; Elisabeth R Garwood; Jessica Gibbs; Nola Hylton; Laura J Esserman
Journal:  Am J Surg       Date:  2006-10       Impact factor: 2.565

4.  Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging.

Authors:  L Esserman; N Hylton; L Yassa; J Barclay; S Frankel; E Sickles
Journal:  J Clin Oncol       Date:  1999-01       Impact factor: 44.544

5.  The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up.

Authors:  Melinda E Sanders; Peggy A Schuyler; William D Dupont; David L Page
Journal:  Cancer       Date:  2005-06-15       Impact factor: 6.860

6.  Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor Histopathology and Angiogenesis in Breast Carcinoma.

Authors:  Laura Esserman; Nola Hylton; Tracy George; Noel Weidner
Journal:  Breast J       Date:  1999-01       Impact factor: 2.431

7.  Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.

Authors:  Ioannis Mylonas; Josef Makovitzky; Udo Jeschke; Volker Briese; Klaus Friese; Bernd Gerber
Journal:  Anticancer Res       Date:  2005 May-Jun       Impact factor: 2.480

8.  Applying the neoadjuvant paradigm to ductal carcinoma in situ.

Authors:  Laura Esserman; Karen Sepucha; Elissa Ozanne; E Shelley Hwang
Journal:  Ann Surg Oncol       Date:  2004-01       Impact factor: 5.344

Review 9.  Standard for the management of ductal carcinoma in situ of the breast (DCIS).

Authors:  Monica Morrow; Eric A Strom; Lawrence W Bassett; D David Dershaw; Barbara Fowble; J a y R Harris; Frances O'Malley; Stuart J Schnitt; S Eva Singletary; David P Winchester
Journal:  CA Cancer J Clin       Date:  2002 Sep-Oct       Impact factor: 508.702

Review 10.  Overview of the biology and management of ductal carcinoma in situ of the breast.

Authors:  E R Frykberg; K I Bland
Journal:  Cancer       Date:  1994-07-01       Impact factor: 6.860

View more
  41 in total

1.  MRI of the breast in patients with DCIS to exclude the presence of invasive disease.

Authors:  Eline E Deurloo; Jincey D Sriram; Hendrik J Teertstra; Claudette E Loo; Jelle Wesseling; Emiel J Th Rutgers; Kenneth G A Gilhuijs
Journal:  Eur Radiol       Date:  2012-02-26       Impact factor: 5.315

2.  The impact of preoperative magnetic resonance imaging on surgical treatment and outcomes for ductal carcinoma in situ.

Authors:  Kaoru Itakura; Juan Lessing; Theadora Sakata; Amy Heinzerling; Eline Vriens; Dorota Wisner; Michael Alvarado; Laura Esserman; Cheryl Ewing; Nola Hylton; E Shelley Hwang
Journal:  Clin Breast Cancer       Date:  2011-03       Impact factor: 3.225

3.  Biologic significance of false-positive magnetic resonance imaging enhancement in the setting of ductal carcinoma in situ.

Authors:  Anjali S Kumar; Daniel F Chen; Alfred Au; Yunn-Yi Chen; Jessica Leung; Elisabeth R Garwood; Jessica Gibbs; Nola Hylton; Laura J Esserman
Journal:  Am J Surg       Date:  2006-10       Impact factor: 2.565

4.  Characterization of ductal carcinoma in situ on diffusion weighted breast MRI.

Authors:  Habib Rahbar; Savannah C Partridge; Peter R Eby; Wendy B Demartini; Robert L Gutierrez; Sue Peacock; Constance D Lehman
Journal:  Eur Radiol       Date:  2011-05-12       Impact factor: 5.315

5.  Ductal Carcinoma in Situ: Quantitative Preoperative Breast MR Imaging Features Associated with Recurrence after Treatment.

Authors:  Jing Luo; Brian S Johnston; Averi E Kitsch; Daniel S Hippe; Larissa A Korde; Sara Javid; Janie M Lee; Sue Peacock; Constance D Lehman; Savannah C Partridge; Habib Rahbar
Journal:  Radiology       Date:  2017-09-14       Impact factor: 11.105

6.  Bilateral contrast-enhanced dual-energy digital mammography: feasibility and comparison with conventional digital mammography and MR imaging in women with known breast carcinoma.

Authors:  Maxine S Jochelson; D David Dershaw; Janice S Sung; Alexandra S Heerdt; Cynthia Thornton; Chaya S Moskowitz; Jessica Ferrara; Elizabeth A Morris
Journal:  Radiology       Date:  2012-12-06       Impact factor: 11.105

7.  Estrogen receptor and breast MR imaging features: a correlation study.

Authors:  Jeon-Hor Chen; Hyeon-Man Baek; Orhan Nalcioglu; Min-Ying Su
Journal:  J Magn Reson Imaging       Date:  2008-04       Impact factor: 4.813

8.  Can algorithmically assessed MRI features predict which patients with a preoperative diagnosis of ductal carcinoma in situ are upstaged to invasive breast cancer?

Authors:  Michael R Harowicz; Ashirbani Saha; Lars J Grimm; P Kelly Marcom; Jeffrey R Marks; E Shelley Hwang; Maciej A Mazurowski
Journal:  J Magn Reson Imaging       Date:  2017-02-09       Impact factor: 4.813

9.  Detection of in situ mammary cancer in a transgenic mouse model: in vitro and in vivo MRI studies demonstrate histopathologic correlation.

Authors:  S A Jansen; S D Conzen; X Fan; T Krausz; M Zamora; S Foxley; J River; G M Newstead; G S Karczmar
Journal:  Phys Med Biol       Date:  2008-09-09       Impact factor: 3.609

10.  Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.

Authors:  Esther H Lips; Rita A Mukhtar; Christina Yau; Jorma J de Ronde; Chad Livasy; Lisa A Carey; Claudette E Loo; Marie-Jeanne T F D Vrancken-Peeters; Gabe S Sonke; Donald A Berry; Laura J Van't Veer; Laura J Esserman; Jelle Wesseling; Sjoerd Rodenhuis; E Shelley Hwang
Journal:  Breast Cancer Res Treat       Date:  2012-09-08       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.